Vero Biotech

What Vero Biotech does

Vero Biotech, Inc. is an Atlanta, Georgia-based commercial-stage biopharmaceutical / medical device company that develops and commercializes the GENOSYL Delivery System (DS), the first and only FDA-approved tankless inhaled nitric oxide (iNO) delivery platform. Founded in 2006 (formerly GeNO LLC) and operating as a privately held, venture-backed business with 101-250 employees, the company targets acute-care hospitals, neonatal intensive care units, surgical suites, MRI environments, and inter-hospital transport services. Its flagship product addresses persistent pulmonary hypertension of the newborn (PPHN) and other hypoxic respiratory failure conditions, serving an addressable patient pool of roughly 100,000 neonates annually in the U.S. alone.

The GENOSYL DS platform replaces traditional large compressed-gas nitric oxide cylinders with a compact, 16 oz disposable cassette that generates iNO on demand at the bedside, paired with a proprietary Smart Feedback System that samples iNO at the patient to maintain precise dose control independent of ventilator settings or flow changes. The device is MRI-conditional up to 3.0 Tesla, FAA-tested for ground, fixed-wing, and rotary-wing transport, and is the only system FDA-approved for low-flow rebreathing anesthesia with major anesthesia machines (GE Aisys, Drager Fabius, Getinge Flow-i). Three product generations have received FDA approval across acute care (2019, 2023), MRI/inter-hospital transport (2020), and rebreathing anesthesia in the surgical suite (2023, 2025). A redundant backup console and automatic cassette transition are designed to minimize clinical interruption. The supporting ecosystem includes the VITA Information Transfer & Analytics web platform, the VERO Knowledge Center for clinician training, and Partnership365, a 24/7/365 service program staffed by registered respiratory therapists.

Vero generates revenue primarily through capital sales of GENOSYL DS hardware to acute-care hospitals, supplemented by recurring single-use disposable cassette consumption. Go-to-market is a direct enterprise field-sales motion targeting hospital procurement, respiratory therapy, and anesthesiology departments, augmented by a group purchasing organization channel via Premier Inc., which provides access to approximately 4,400 U.S. hospitals and 250,000 providers. Pricing is quote-based and not publicly disclosed. The company has raised cumulative disclosed funding of roughly $245M+ from 2021-2024 across equity (Runway Growth Capital, MVM Partners, Petrichor) and a $65M debt facility, and has been recognized with the AARC Zenith Award (2024), Premier's Technological Breakthrough designation (2023), and the Georgia Bio Golden Helix Innovation Award (2022).

Name

Vero Biotech

Legal name

Vero Biotech, Inc.

Website

https://vero-biotech.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

Vero Biotech is an Atlanta-based commercial-stage medical device company that develops and commercializes the GENOSYL Delivery System, the first and only FDA-approved tankless inhaled nitric oxide delivery platform for acute-care hospitals, NICUs, surgical suites, MRI, and inter-hospital transport. It serves U.S. hospitals via direct enterprise sales and Premier Inc. GPO.

Ownership category

akta.pro rank

Product category

Respiratory Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Inhaled nitric oxide delivery
• Respiratory medical devices
• Neonatal intensive care
• Pulmonary hypertension treatment
• Tankless gas delivery

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. GENOSYL Delivery System Sales: Commercial-stage medical device company generating revenue from sale of GENOSYL DS hardware and disposable cassettes to acute care hospitals. Device sold to hospitals for use in ICU, transport, MRI, and surgical suite settings. Cassettes are single-use disposables requiring ongoing repurchase.
2. GENOSYL DS Commercialization: Revenue generated through commercialization of FDA-approved GENOSYL Delivery System for treating severe pulmonary hypertension in hospitals. Series E funding from MVM Partners specifically supporting growth and market adoption.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Vero Biotech manufactures and commercializes the GENOSYL Delivery System (DS), the first and only FDA-approved tankless inhaled nitric oxide (iNO) delivery system. The system generates iNO at the bedside using a patented disposable cassette, eliminating the need for large compressed gas tanks, and is approved for use across ICU, inter-hospital transport, MRI, and low-flow anesthesia settings. Revenue is generated through sales of the GENOSYL DS hardware to acute care hospitals and ongoing purchases of single-use cassettes.

Product overview

VERO Biotech offers a focused product portfolio anchored by the GENOSYL Delivery System (DS), a proprietary tankless inhaled nitric oxide (iNO) delivery system that is the first and only FDA-approved tankless system in its category. The portfolio consists of the GENOSYL DS hardware (available in multiple generations), the GENOSYL therapeutic gas cassette as a single-use consumable, the VITA Information Transfer & Analytics web platform for clinician data access, and the Partnership365 support program staffed by registered respiratory therapists. The system is designed for use across multiple care settings — ICU, inter-hospital transport, MRI suites, and low-flow anesthesia — with a Smart Feedback System for dose precision and built-in redundant backup. The VERO Knowledge Center provides on-demand training and education resources.

Differentiator

Problem solved

Functional benefit

Brands

• GENOSYL: The GENOSYL Delivery System (DS) is VERO Biotech's flagship product - a tankless, portable inhaled nitric oxide (iNO) delivery system for treating pulmonary hypertension and hypoxic respiratory failure in neonates.
• VITA
• Partnership365

Products and services

• GENOSYL Delivery System (DS) FDA-approved tankless inhaled nitric oxide (iNO) delivery system that generates and delivers iNO at the bedside using a disposable cassette. Features a Smart Feedback System for precise dosing, redundant backup console, and is approved for use in ICU, ground/fixed-wing/rotary-wing transport, MRI Suite, and low-flow anesthesia environments. Sold to acute care hospitals and health systems.
• GENOSYL DS Cassette A compact, 16 oz single-use, disposable cassette that stores at the bedside and generates inhaled nitric oxide on demand using patented technology. Eliminates tank management and reprocessing; automatic cassette transition ensures continuous, uninterrupted dosing. Sold as a recurring consumable to GENOSYL DS customers.
• GENOSYL (nitric oxide) gas, for inhalation Inhaled nitric oxide therapeutic gas indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in conjunction with ventilatory support and other appropriate agents.
• VITA Information Transfer & Analytics Web-based platform providing information transfer and analytics capabilities for GENOSYL DS users. Clinicians log in to access data related to the delivery system, with an associated mobile app (app.vita.vero-biotech.com) for on-the-go access.
• Partnership365 Service and Support 24/7/365 support program connecting customers with experienced registered respiratory therapists (10+ years bedside experience) for training, troubleshooting, clinical support, medical information, inventory management, and technical support. Includes on-demand training and education via the VERO Knowledge Center.

Quantifiable outcome

• Setup time reduced to less than 2 minutes
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Premier Inc.coreChannel Partner/ Reseller/ Distributor · 14 June 2023Premier is a leading healthcare improvement company uniting approximately 4,400 U.S. hospitals and 250,000 other providers. VERO Biotech recognized as Innovative Supplier at Premier's Annual Supplier Innovation Celebration and Breakthroughs Conference.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Vapotherm: Vapotherm delivers respiratory gas therapy (high-velocity nasal insufflation) to neonatal and adult patients in acute care settings. Addresses overlapping NICU/respiratory customer base with a different delivery modality but competes for similar hospital respiratory therapy budgets.

Broad incumbents

• Becton Dickinson (BD): BD is a major medical device manufacturer with broad hospital drug delivery, infusion, and medication management offerings. Competes broadly for hospital formulary and connected therapeutics spend with comparable enterprise sales motion to acute care customers.
• Masimo: Masimo offers patient monitoring and connected care platforms in the hospital setting, comparable to Vero's VITA Information Transfer & Analytics platform and Smart Feedback System. Operates in adjacent categories (monitoring vs. delivery) with overlapping hospital customers.
• ICU Medical: ICU Medical manufactures drug delivery and infusion systems for acute care hospitals, overlapping with Vero's smart drug delivery and clinical workflow integration capabilities. Comparable customer base (hospital ICUs) and adjacent product category (connected therapeutic delivery).

Others

• Getinge: Getinge's Flow-i anesthesia machine is one of the platforms certified for use with GENOSYL DS. Functions as a complementary vendor in the same surgical suite setting rather than a competitor, but is a relevant comparable for acute care hospital equipment peers.
• Drägerwerk: Dräger manufactures anesthesia machines (Fabius) and ventilators that GENOSYL DS integrates with for low-flow rebreathing anesthesia. They are a key interoperability partner rather than direct competitor, but operate in the same ICU/OR acute care environment.
• GE HealthCare: GE HealthCare's Aisys anesthesia machine is one of the platforms GENOSYL DS integrates with for low-flow anesthesia. Operates as a complementary equipment vendor in the same OR acute care environment rather than a direct iNO competitor.
• Inogen: Inogen specializes in portable respiratory gas delivery (oxygen concentrators) for respiratory patients. Functions as an adjacent respiratory therapy company with a hospital and home-care presence, indirectly comparable as a respiratory drug/gas delivery business.

Direct peers

• Beyond Air: Beyond Air developed the LungFit PH, a tankless inhaled nitric oxide delivery system that received FDA approval in 2024. Directly competes with GENOSYL DS in the same PPHN indication with a similar portable, on-demand NO generation approach.
• Mallinckrodt Pharmaceuticals: Mallinckrodt markets INOmax (inhaled nitric oxide), the established tank-based iNO delivery system that is the primary competitor to Vero Biotech's GENOSYL DS in U.S. hospitals. Directly comparable product category, same indication (PPHN, hypoxic respiratory failure), and overlapping hospital customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/verobiotech
• LinkedInlinkedin.com/company/vero-biotech
• Instagraminstagram.com/verobiotech
• Xx.com/verobiotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds8 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vero Biotech